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Abstract
Background: No official German translation exists for the 50-item Expanded Prostate Cancer Index Composite
(EPIC), and no minimal important difference (MID) has been established yet. The aim of the study was to translate
and validate a German version of the EPIC with cultural adaptation to the different German speaking countries
and to establish the MID.
Methods: We translated and culturally adapted the EPIC into German. For validation, we included a consecutive
subsample of 92 patients with localized prostate cancer undergoing radical prostatectomy who participated the
Prostate Cancer Outcomes Cohort. Baseline and follow-up assessments took place before and six weeks after
prostatectomy in 2010 and 2011.
We assessed the EPIC, EORTC QLQ-PR25, Feeling Thermometer, SF-36 and a global rating of health state change
variable. We calculated the internal consistency, test-retest reliability, construct validity, responsiveness and MID.
Results: For most EPIC domains and subscales, our a priori defined criteria for reliability were fulfilled (construct
reliability: Cronbach’s alpha 0.7–0.9; test-retest reliability: intraclass-correlation coefficient ≥ 0.7). Cross-sectional
and longitudinal correlations between EPIC and EORTC QLQ-PR25 domains ranged from 0.14–0.79, and 0.06–0.5
and 0.08–0.72 for Feeling Thermometer and SF-36, respectively. We established MID values of 10, 4, 12, and 6 for
the urinary, bowel, sexual and hormonal domain.
Conclusion: The German version of the EPIC is reliable, responsive and valid to measure HRQL in prostate cancer
patients and is now available in German language. With the suggested MID we provide interpretation to what
extent changes in HRQL are clinically relevant for patients. Hence, study results are of interest beyond German
speaking countries.
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Background
Prostate cancer is one of the most prevalent cancers in
men. Due to the growing number of long-term survival
rates [1], maintenance of health-related quality of life
(HRQL) is crucial for prostate cancer patients and
should be taken carefully into account when planning
individual treatment strategies [2]. Data on effects and
side effects [3] of different treatment modalities on
HRQL are of great value to guide the physicians’ advice
and patients’ decision on choice of treatment. Therefore,
patient-reported outcome measures are required that ap-
propriately assess relevant aspects of HRQL and that
have well-established psychometric properties, i.e. the
measures should be reliable, valid and able to detect pa-
tient important changes in HRQL over time (minimal
important difference, MID). A well-established MID of
an instrument is particularly important for clinicians and
researchers because it shows whether a specific change
score derived from assessments before and after an
intervention actually reflects a difference that is relevant
for the patient.
Several generic and disease specific HRQL instruments
have been introduced and recommended for prostate
cancer patients so far [4]. One of the most established
and frequently used instrument focussing on disease-
specific aspects of prostate cancer and its therapies is
the 50-item Expanded Prostate Cancer Index Composite
(EPIC) [5]. The EPIC was evolved from the UCLA-
Prostate Cancer Index (UCLA-PCI) [6] by an expert
panel. Originally developed in the U.S. in English lan-
guage, the EPIC has been translated and validated into
several other languages such as Korean [7], Japanese [8],
Brazilian [9] and Spanish [10]. In addition, two short
form versions have been introduced, a 26-item (EPIC-
26) [11] and a 16-item (EPIC-CP) [12] version. Although
short versions of questionnaires are generally useful in
clinical practice, a loss of precision in the assessment is
inevitable when using them compared to the extensive
versions. Therefore, the original and extensive EPIC 50-
item version is valuable whenever detailed assessment is
required. Compared to the other frequently used instru-
ment, the European Organization for the Research and
Treatment of Cancer Quality of Life Questionnaire–
Prostate 25 (EORTC QLQ-PR25) tool [13], the EPIC
seems to provide a better balanced performance to as-
sess more in depths the various side effects independent
of treatment modality finally chosen.
To our knowledge, no MID of the original EPIC 50-
item version has been established so far, and, except for
a translation of the EPIC-26 [14], no validated German
version exists. Since over 100 million people worldwide
are native German speakers, a German version of this
important instrument is of great value. The aims of this
study were to translate and validate the German version
of the EPIC with cultural adaptation to the different
German speaking countries Germany, Austria and
Switzerland, and to establish the MID for each domain
of the instrument.
Methods
The unabridged version of the Material and methods
section is presented in Additional file 2.
The Expanded Prostate Cancer Index Composite (EPIC)
The EPIC consists of 50 items with Likert type response
options contributing to the four domains Urinary,
Bowel, Sexual and Hormonal. Each domain is divided
into the two subscales Functional and Bother assessing
symptoms severity and the extent of symptom-related
HRQL impairment. The urinary domain is additional di-
vided into the two distinct Incontinence and Irritation/
Obstruction subscales. Domains and subscales are pre-
sented in 0–100 scales with higher scores representing
better HRQL.
Translation and cultural adaptation
The translation and cultural adaptation process was
based on the recommendations of the ISPOR Task Force
international expert group [15] and followed a sequential
forward and backward translation approach (Fig. 1).
Two professional translators translated the original Eng-
lish EPIC version into German. In a consensus meeting,
five experts assessed the consistency of the translations,
judged their face validity and agreed on a first German
version. This first version was pretested in cognitive
debriefings in five prostate cancer patients who agreed
on a second German version. A professional translator
translated this version back into English language which
was then presented to the author of the original English
version [5]. The second German version then was pre-
tested in the three German speaking countries (Austria,
Germany and Switzerland), each of them within thirty
patients to assess the need for cultural adaptation. Fi-
nally, the experts agreed on a third, final version of the
German version of the EPIC (Additional file 2).
Study population and study design
For the validation study, we recruited a subsample of
patients who participated the Prostate Cancer Out-
comes Cohort (proCOC) [16] who had a diagnosis of
localized prostate cancer and underwent robotic radical
prostatectomy within the Department of Urology of the
University Hospital of Zurich between November 2008
and December 2010. The local Ethical Committee of
the Canton of Zurich approved the study.
Baseline assessments took place after the diagnosis
and before radical prostatectomy and included assess-
ments of the EPIC and the validation instruments
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(internal consistency and cross-sectional construct
validity). To assess test-retest reliability, a subgroup of
participants completed the EPIC a second time one to
two weeks later, before initiation of treatment. Follow-
up assessments were conducted six weeks after treat-
ment (longitudinal construct validity, responsiveness
and MID).
Validation instruments
The European Organization for the Research and
Treatment of Cancer Quality of Life Questionnaire–
Prostate 25 (EORTC QLQ-PR25) [13] is a prostate spe-
cific additional tool to the general quality of life instru-
ment EORTC QLQ-C30 [17]. It includes 25 items with
a 4-point Likert scale that contribute to the sexual
activity and sexual functioning (scores 0–100; higher
scores = higher level of functioning) and urinary symp-
toms, bowel symptoms and hormonal treatment-
related symptoms scales (scores 0–100, higher score =
higher level of problems) [13]. For the EORTC-QLQ-
C30, a MID of 5–10 has been established [17, 18], no
MID has been specifically reported so far for the pros-
tate additional tool.
The Feeling Thermometer assesses generic health sta-
tus on an analogue scale presented as a thermometer
with 100 marked intervals (0 = dead to 100 = perfect
health), a MID of 5 has been reported [19–21].
The SF-36 version 2.0 is a generic quality of life instru-
ment that consists of 36 items describing 8 domains
(scores 0–100; higher scores = better perceived state of
health) [22, 23]. MID between 7 and 12 have been sug-
gested specifically for prostate cancer survivors [24].
The patients also rated the global change of their
health state since baseline (after treatment) on a 5-point
Likert scale at follow up, ranging from − 2 (my health
state worsened much) to + 2 (my health state improved
much).
Statistical analysis
We assessed internal consistency of the EPIC scores by
Cronbach’s alpha (adequate internal consistency a priori
defined: 0.7–0.9) and test-retest reliability by intraclass
Fig. 1 Translation process. The progress of for- and backward translation into German language including two rounds of pilot testing as well as
cultural adaption
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Table 1 Mean scores of the EPIC summary domains and subscales and the validation instruments at baseline and at 6 weeks
follow-up after robotic assisted radical prostatectomy and changes from baseline to follow-up
Measurement Baseline (n = 92)a 6-weeks follow-up (n = 92)a Change from baseline to follow-up (n = 92)a
EPIC domain-specific summary scores
Urinary 90.0 (11.9) 61.7 (18.5) −28.3 (18.7)
Bowel 94.4 (7.8) 87.8 (11.6) −6.8 (11.0)
Sexual 61.1 (20.4) 17.5 (12.1) −44.0 (23.0)
Hormonal 90.5 (11.3) 87.2 (13.2) −3.3 (12.9)
Urinary subscales
Function 96.2 (9.6) 54.6 (21.8) −41.6 (22.1)
Bother 85.6 (15.2) 66.8 (18.3) −18.8 (19.5)
Incontinence 94.8 (13.4) 37.2 (27.4) −57.6 (27.4)
Irritation/obstruction 88.8 (12.9) 77.0 (17.4) −11.2 (18.8)
Bowel subscales
Function 93.8 (8.6) 88.3 (10.7) −5.7 (11.4)
Bother 95.1 (8.9) 87.4 (14.4) −7.7 (13.3)
Sexual subscales
Function 56.7 (21.9) 9.1 (11.3) −47.1 (22.4)
Bother 72.5 (23.8) 35.9 (28.2) − 37.2 (32.8)
Hormonal subscales
Function 90.1 (12.7) 85.0 (14.9) −5.1 (15.4)
Bother 90.8 (11.3) 88.8 (12.8) −1.9 (12.3)
EORTC QLQ-PR25 symptom scales
Urinary symptoms 17.0 (16.0) 40.1 (20.8) 22.9 (19.4
Bowel symptoms 4.5 (7.9) 7.8 (9.5) 2.6 (10.3)
Hormonal treatment-related symptoms 6.5 (9.7) 11.9 (12.0) 4.7 (11.8)
EORTC QLQ-PR25 functional scales
Sexual activity 59.0 (25.4) 22.5 (24.6) −25.0 (30.6)
Sexual functioning 79.5 (19.0) 38.8 (19.4) − 40.4 (25.6)
Feeling Thermometer 79.8 (15.5) 71.01 (17.3) −6.4 (19.7)
SF-36
Physical Functioning 96.7 (6.5) 77.3 (19.8) −19.4 (20.1)
Role-Physical 89.3 (19.9) 58.3 (27.0) − 31.0 (29.8)
Bodily Pain 88.9 (17.9) 74.8 (27.4) −17.2 (31.1)
General Health 74.7 (16.5) 71.1 (17.0) −3.5 (16.1)
Vitality 38.6 (8.9) 31.3 (12.3) −7.2 (11.5)
Social Functioning 85.3 (20.7) 72.3 (28.2) −13.0 (31.1)
Role-Emotional 88.9 (18.9) 74.8 (27.4) −14.1 (26.9)
Mental Health 30.9 (6.7) 29.9 (8.3) −1.0 (7.5)
Abbreviations: EPIC Expanded Prostate Cancer Index Composite, ERTC QLQ-PR25 European Organization for the Research and Treatment of Cancer Quality of Life
Questionnaire–Prostate 25 t
aMissing values: All EPIC scores: 0–2, except for Sexual function subscale: Baseline = 5/follow-up = 4/change = 8; EORTC QLQ-PR25: Urinary symptoms: 5/3/8; Bowel
symptoms: 8/3/11; Hormonal treatment related symptoms: 8/2/10, Sexual activity: 7/3/10, Sexual functioning: 23/57/62; Feeling Thermometer: 24/9/26; SF-36: no
missing values
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correlation coefficients (ICC; a priori defined: ≥0.70
[25]). To assess cross-sectional and longitudinal con-
struct validity we used Pearson or Spearman’s rank cor-
relation coefficients at baseline and at 6 weeks follow-up
between the EPIC domain scores and the validation
measures or the change sores, respecitvely. We a priori
expected strong correlations (≥0.5) between the EPIC
and the corresponding EORTC QLQ-PR25 scores and
moderate correlations (0.3–0.5) between the EPIC and
the Feeling Thermometer and selected SF-36 domain
scores.
To quantify responsiveness, we assessed the standar-
dised response mean (SRM) as the mean change score
divided by SD of change score (a priori stronger effect
sizes in urinary/sexual compared to bowel/hormonal
domains expected). We established the MID by tri-
angulation and used both anchor-based approaches
(using EPIC domain change scores against the anchors
“worsened” and “remained the same” of the global rat-
ing of health state chance variable) and distribution-
based approaches (standard error of measurement
[SEM], Cohen’s effect size, empirical rule effect size)
[26]. Analysis were performed using STATA version
13 [27].
Results
Ninety two consecutive participants of the proCOC
study with localized prostate cancer and a mean age of
62.3 ± 7.1 years participated in the validation study and
completed baseline assessments (before treatment) and
6 week follow-up assessments (after treatment). Mean
scores of the EPIC summary domains and subscales
and the validation instruments at baseline and at
6 weeks follow-up after robotic assisted radical prosta-
tectomy and changes from baseline to follow-up are
presented in Table 1. A subsample of 44 participants of
proCOC with a mean age of 62.5 ± 7.4 years completed
the EPIC a second time before treatment to assess
test-retest reliability, on average with 10.9 ± 13.3 days
between the assessments.
Internal consistency and test-retest reliability
Characteristics of the EPIC domain and subscale
scores and the results on internal consistency and re-
producibility are presented in Table 2. In general,
urine and sexual domain scores of the patients de-
creased to a greater extent from baseline to 6 weeks
follow-up than did bowel and hormonal domain
scores. For the majority of the domain and subscale
scores, Cronbach’s alpha values were within our a
priori defined boundaries and test retest reliability
above the threshold; ICCs of the domain scores were
between 0.69–0.87, of the subscales between 0.43–
0.92.
Construct (convergent) validity
Tables 3 and 4 show correlation coefficients between
the EPIC domain scores and the other validation in-
struments according to whether they fulfilled our a
priori assumptions regarding strength of correlation.
Cross-sectional correlations (Table 3) between the EPIC
and the EORTC QLQ-PR25 domains ranged from
0.14–0.79. Correlations between the EPIC domains and
the Feeling Thermometer and the SF-36 domains were
weaker and ranged from 0.06–0.50 and 0.08–0.72, re-
spectively. In most cases, correlations were stronger at
6 weeks follow-up than at baseline. Longitudinal corre-
lations (Table 4) between the change scores of the EPIC
and EORTC QLQ-PR25 domains were all > 0.5. Change
score correlations between the EPIC domains and the
Table 2 Domain-specific summary and subscale scores of the
German version of the EPIC at baseline and 6 weeks follow-up
and results on internal consistency and reproducibilitya
EPIC domains No. of
items
Cronbach’s alpha
reliability coefficienta
(n = 92)
Test-retest reliability
(ICC, 95% CI) (n = 44)
Domain Summary
Scores
Urinary 12 0.87 0.79 (0.65–0.88)
Bowelb 14 0.80 0.79 (0.64–0.88)
Sexualb 13 0.92 0.87 (0.77–0.93)
Hormonal 11 0.81 0.69 (0.50–0.82)
Urinary subscales
Function 5 0.64 0.43 (0.16–0.65)
Bother 7 0.85 0.81 (0.68–0.89)
Incontinence 4 0.82 0.54 (0.30–0.72)
Irritation/
obstruction
7 0.81 0.82 (0.69–0.90)
Bowel subscales
Functionb 7 0.51 0.78 (0.63–0.88)
Bother 7 0.81 0.77 (0.62–0.87)
Sexual subscales
Function b 9 0.92 0.92 (0.87–0.96)
Botherb 4 0.85 0.68 (0.47–0.81)
Hormonal subscales
Function 5 0.58 0.61 (0.38–0.76)
Bother 6 0.69 0.65 (0.43–0.79)
Abbreviations: EPIC Expanded Prostate Cancer Index Composite, ICC intraclass
correlation coefficient
aCronbach’s alpha calculated using baseline scores
bMissing values: Bowel summary: 1, Sexual summary: 1, Bowel function: 2,
Sexual function: 5, Sexual bother: 1
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Table 3 Correlation coefficientsa for the EPIC domain summary scores with validation instruments at baseline and follow-up
(n = 92b)
Baseline 6 weeks follow-up
EPIC domain summary scores EPIC domain summary scores
Urinary Bowel Sexual Hormonal Urinary Bowel Sexual Hormonal
EORTC PR-25
Urinary symptoms −0.70 −0.79
Bowel symptoms −0.42 −0.64
Hormonal treatment −0.58 −0.70
Sexual activity 0.68 0.14
Sexual functioning 0.66 0.25
Feeling Thermometerb 0.12 0.18 0.06 0.37 0.37 0.28 0.27 0.50
SF-36
Physical Functioning 0.40 0.47
Social Functioning 0.14 0.13 0.49 0.19
Bodily Pain 0.22 0.56
Role Emotional 0.08 0.61 0.36 0.62
General Health 0.47 0.59
Vitality 0.60 0.72
Abbreviations: EPIC Expanded Prostate Cancer Index Composite, EORTC PR25 European Organization for the Research and Treatment of Cancer Quality of Life
Questionnaire–Prostate 25; Hormonal treatment = Hormonal treatment-related symptoms
aCorrelation coefficients according to distribution: Spearman’s rank correlation coefficients for not-normally distributed scores at baseline and 6 weeks follow-up.
Correlation coefficients are boldface font when they met our assumptions and normal font when they were higher or lower than expected
bMissing values: Correlations between EPIC and EORTC PR-25 domains: 3 to 13, except for EPIC sexual and EORTC PR25 sexual functioning domains (baseline = 23/
follow-up = 57); Correlations between EPIC domains and Feeling Thermometer: baseline = 24–25/follow-up = 9–10; Correlations between EPIC and SF-36 domains:
all time points = 0–2
Table 4 Correlation coefficientsa for the EPIC domain summary scores with validation instruments between change scores from
baseline to follow-up (n = 92b)
Change from baseline to follow-up
EPIC domain summary scores
Urinary (95% CI) Bowel (95% CI) Sexual (95% CI) Hormonal (95% CI)
EORTC PR-25
Urinary symptoms −0.69 (− 0.79, − 0.56)
Bowel symptoms −0.53 (− 0.67, − 0.35)
Hormonal treatment −0.54 (− 0.68, − 0.36)
Sexual activity 0.58 (0.41, 0.71)
Sexual functioning 0.55 (0.24, 0.76)
Feeling Thermometerb 0.27 (0.03, 0.48) 0.07 (−0.18, 0.21) 0.21 (−0.04, 0.43) 0.50 (0.29, 0.66)
SF-36
Physical Functioning 0.28 (0.08, 0.46)
Social Functioning 0.08 (−0.13, 0.28)
Bodily Pain 0.34 (0.14, 0.51)
Role Emotional 0.30 (0.10, 0.48) 0.20 (−0.01, 0.39) 0.45 (0.27, 0.60)
General Health 0.42 (0.23, 0.58)
Vitality 0.48 (0.30, 0.62)
Abbreviations: EPIC Expanded Prostate Cancer Index Composite, EORTC PR25 European Organization for the Research and Treatment of Cancer Quality of Life
Questionnaire–Prostate 25; Hormonal treatment = Hormonal treatment-related symptoms. CI=Confidence Interval
aCorrelation coefficients according to distribution: Pearson correlations coefficients for normally distributed change scores. Correlation coefficients are boldface
font when they met our assumptions and normal font when they were higher or lower than expected
bMissing values: Correlations between EPIC and EORTC PR-25 domains: 3 to 13, except for EPIC sexual and EORTC PR25 sexual functioning domains (=62);
Correlations between EPIC domains and Feeling Thermometer: change = 27–28; Correlations between EPIC and SF-36 domains: all time points = 0–2
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other validation instruments were weaker and ranged
from 0.07–0.50.
Responsiveness to change and MID
The SRMs of the EPIC change scores were − 1.51 for
the urinary domain, − 0.62 for the bowel, − 1.91 for the
sexual and − 0.26 for the hormonal domain. Table 5
shows the mean changes in the EPIC domains accord-
ing to the global ratings of health state change. Table 6
summarises the anchor and distribution based esti-
mates. We established the MID by triangulation and
suggest a MID of 10 for the urinary domain, 4 for the
bowel domain, 12 for the sexual domain and 6 for the
hormonal domain. Additional file 1: Tables S1 and S2
show the results for the EPIC subscales; in summary,
we established for the urinary subscales MID between
9 and 12, for the bowel subscales 4 and 5, for the sex-
ual subscales 11 and 13, and for the hormonal sub-
scales 6 and 7 (Additional file 1).
Discussion
With this study we provide a culturally adapted and
thoroughly validated German version of the widely used
EPIC 50-item questionnaire. The German EPIC showed
good internal consistency, reproducibility and construct
validity and was responsive to detect changes in patients
with localized prostate cancer after radical prostatec-
tomy. We established an MID of 10 for the urinary, of 4
for the bowel, of 12 for the sexual and of 6 for the hor-
monal EPIC domains, respectively.
Compared to the participants of the original American
development study [5] and some translation studies [7, 9],
the patients from our sample achieved slightly higher but
similar EPIC scores at baseline. The exception was the sex-
ual domain and subscales, for which our patients scored
much higher, indicating a better HRQL in sexual aspects
before treatment compared to the other populations.
All of the domain and most of the subscale scores
fulfilled the a priori defined thresholds for consistency
and test-retest reliability. The few exceptions were the
urinary function subscale, which reached an insuffi-
cient reproducibility, and, together with the bowel and
hormonal function subscales, also a low reliability.
Interestingly, the test-retest reliability and internal
consistency values of the EPIC domains and subscales
in our study were very similar to those presented in
the original development and validation study [5].
The usually moderate to strong correlations between
the EPIC and the corresponding EORTC QLQ-PR25
domains suggest good convergent construct validity and
confirm that the domains of the two questionnaires re-
flect very similar constructs of HRQL in prostate cancer.
The weaker correlations with selected and more generic
SF-36 domains and the generic Feeling Thermometer
were expected. Interestingly, the EPIC hormonal domain
showed mostly the highest correlations with the more
generic scales.
As expected, the urinary and sexual domains were
much more responsive to the treatment than the
bowel and hormonal domains. Radical prostatectomy
predominantly affects sexual and urinary aspects of
HRQL, especially soon after surgery. In contrast, other
therapies such as radiotherapy would have affected
rather bowel and hormonal components.
To our knowledge, we propose for the first time MID
for the EPIC 50-item version. This is surprising, since
there is growing awareness of the fact that outcome
measurements need to be able to detect clinically rele-
vant changes when used for evaluative purposes. MIDs
have already been suggested for the two EPIC short
form versions. The EPIC-26 [11] uses the same scoring
system as the EPIC 50-item and retained the domain
structure (only the urinary domain dropped and using
the two urinary subscales urinary incontinence and
urinary irritation/obstruction). Our suggested MIDs
were mainly in the range of the established MIDs for
the EPIC-26 (6–9 for the urinary incontinence, 5–7 for
the urinary irritation/obstruction, 4–6 for bowel, 10–12
for sexual and 4–6 for the hormonal domain) [28]. The
scores of the 16-item EPIC-CP [12] domains range
from 0 to 12 and, therefore, the MIDs are not compar-
able. However, also for this 16 item version, the MID
was highest estimated for the sexual domain (1.6) and
lowest for the vitality/hormonal (1.0) (MID for other
Table 5 Mean changes in the EPIC domains according to global rating of health state change at follow-up
Global rating of change of
state of health by
treatmenta
EPIC Urinary domain EPIC Bowel domain EPIC Sexual domain EPIC hormonal domain
m (SD) m (SD) m (SD) m (SD)
Worsened much (n = 8) −41.6 (21.3) −15.0 (17.8) −56.0 (26.5) −17.3 (11.5)
Worsened (n = 40) − 33.2 (18.4) −7.7 (9.8) − 49.0 (19.2) − 5.7 (14.1)
Remained the same (n = 31) −21.8 (15.7) − 5.1 (9.9) −36.0 (24.2) 0.8 (5.5)
Improved (n = 6) − 21.5 (15.2) −4.5 (5.0) −36.0 (23.1) 0.8 (11.1)
Improved much (n = 6) −16.2 (20.1) 4.3 (8.1) −41.3 (25.8) 9.8 (15.0)
Abbreviations: EPIC Expanded Prostate Cancer Index Composite
aGlobal rating of health state chance on the 5-point Likert scale ranging from −2 (my health state worsened much) to + 2 (my health state improved much)
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domains: 1.3 for urinary irritation/obstruction, 1.2 for
bowel, 1.0 for urinary incontinence) [29].
Strengths of our study are the rigorous adherence to
the international ISPOR guidance for the translation and
validation of patient reported outcomes. The cultural
adaption also took differences in mentalities between the
German speaking countries into consideration and re-
sulted in an instrument applicable in all of them. Fur-
thermore, the assessments took place in a prospective
cohort study with a priori defined hypothesis regarding
results.
One limitation of the validation part of our study is
that we included patients who underwent radical pros-
tatectomy only and focused on short-term changes
(6 weeks after treatment) to assess responsiveness and
MID of the EPIC. As already stated and expected, the
HRQL aspects of the domains urinary and sexual are
more affected by this kind of treatment than the bowel
and hormonal domains, which might challenge the
generalizability of our results to prostate patient under-
going other treatments such as external radiation or
hormonal deprivation therapy, experiencing other side
effects. However, it would be interesting to replicate the
analyses in prostate cancer patients undergoing other
treatments, particularly the assessment of the MID in
these populations. Another limitation is that we used
the anchors “worsened” and “remained the same” of the
global rating of health state chance variable as anchor
based approach to establish the MIDs. This implies that
we assume the differences between “worsened” and
“remained the same” to reflect to be minimally import-
ant for patients, which we cannot be sure about. Unfor-
tunately, the anchor EORTC QLQ-PR25 resulted in
somewhat implausible values, probably due to the
transformation of both instruments to 0–100 scales and
the reverse scaling of some counterpart domains. An
additional limitation is that for the method we used to
test cross-sectional and longitudinal construct validity,
correlation coefficients, the sample size of 92 patients is
rather small. However, the consequence of a smaller
sample size is not different correlation coefficients
(which depends more on how the population is se-
lected) but that the estimates are more imprecise, i.e.
that the confidence intervals around correlation coeffi-
cients are wider compared to confidence intervals of
correlation coefficients based on larger sample sizes.
Conclusions
The German version of the EPIC showed to be a reliable,
valid and responsive instrument to detect changes in
HRQL components due to prostate cancer treatment.
With the suggested MIDs we provide interpretation to
what extent changes in HRQL are clinically relevant for pa-
tients. Hence, study results are of interest beyond German
speaking countries.
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according to global rating of health state change at follow-up. Table S2:
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